rdrp inhibitor

LabMol-319 is a potent Zika virus (ZIKV) NS5 RdRp inhibitor with antiviral activity for the study of ZIKV virus.

AS-136A is an orally active measles virus RNA-dependent RNA polymerase (RdRp) inhibitor with antiviral activity that inhibits measles virus and blocks viral RNA synthesis.

Setrobuvir (ANA-598) is an orally active non-nucleoside HCV NS5B polymerase inhibitor with inhibitory effects on de novo RNA synthesis and primer extension with IC50s between 4 and 5 nM. setrobuvir shows good binding affinity for SARS-CoV-2 RdRp and induces inhibition of RdRp.

Galidesivir hydrochloride is an inhibitor of viral RNA-dependent RNA polymerase (RdRp). It inhibits SARS-CoV-2 by tightly binding to its RdRp.

Galidesivir is a viral RNA-dependent RNA polymerase (RdRP) inhibitor and broad spectrum antiviral nucleotide.In vitro, galidesivir displays antiviral activity against a range of RNA viruses, including bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses, and flaviviruses (EC50values range from 3 μM to >100 μM). Galidesivir protects against Ebola and Marburg viral infection in animal models.

GS-443902 trisodium (GS-441524 triphosphate trisodium), the active triphosphate metabolite of Remdesivir (GS-5734), serves as a potent inhibitor of viral RNA-dependent RNA-polymerases (RdRp), displaying inhibitory concentrations (IC50) of 1.1 μM for RSV RdRp and 5 μM for HCV RdRp.

Sotetsuflavone, with an IC50 of 0.16 μM, stands as the most active compound in its series, acting as a potent inhibitor of DENV-NS5 RdRp (Dengue virus NS5 RNA-dependent RNA polymerase).

Simeprevir (TMC435) is a potent HCV NS3 4A protease inhibitor, and inhibits HCV replication with EC50 of 8 nM.

BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase (RdRp) inhibitor, is effective orally and can inhibit various SARS-CoV-2 variants. It exhibits EC 50 values of 0.62 µM for SARS-CoV-2 and 0.14 µM for HCoV-229E, demonstrating potent anti-pancoronavirus activity at submicromolar concentrations. Additionally, BPR3P0128 displays synergistic antiviral effects when used in combination with Remdesivir [1].

Suramin is a dual-function inhibitor of SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) and protein tyrosine phosphatases (PTPases), with antiparasitic, anticancer, and anti-angiogenesis properties, inhibiting sirtuins and DNA topoisomerase II.

DENV-IN-4 is a potent inhibitor of DENV (DENV EC50=4.79 μM, Vero CC50>100 μM, SI>20.9), demonstrating antiviral efficacy through concentration-dependent reduction of DENV2 expression and inhibition of RNA-dependent RNA polymerase (RdRp) activity.

ZIKV-IN-1 is a potent inhibitor of Zika virus (EC50: 2.8 μM, EC90: 6.8 μM) with anti-ZIKV effects and low cytotoxicity, showing high affinity for the RdRp domain of ZIKV.

CYP2C19-IN-1 is a potent, non-genotoxic, non-hepatotoxic inhibitor of CYP2C19. CYP2C19-IN-1 inhibits RNA-dependent RNA polymerase (RdRP) (Ki: 6.16 μM) and can be used to study Zika virus (ZIKV) infection.

NITD-2 is a dengue virus (DENV) polymerase inhibitor, inhibits the DENV RdRp-mediated RNA elongation. NITD-2 penetrates cell membrane poorly. Dengue virus (DENV) is the most prevalent mosquito- borne viral pathogen in humans. Neither vaccine nor antiviral therapy is currently available for DENV.

13-TP is an inhibitor of SARS-CoV-2. It effectively suppresses in vitro RNA synthesis catalyzed by the central replication-transcription complex (C-RTC, nsp12-nsp7-nsp82) of SARS-CoV-2. 13-TP fully inhibits RdRp polymerase activity and obstructs the complete extension of some primer RNAs.

GS-441524 was shown to be a safe and effective treatment for feline infectious peritonitis (FIP). The optimum dosage was found to be 4.0 mg kg SC q24h for at least 12 weeks

HeE1-2Tyr, a pyridobenzothiazole compound, is a potent inhibitor of flavivirus RNA-dependent RNA polymerases (RdRp). It significantly inhibits the RdRp activity of West Nile, Dengue, and SARS-CoV-2 in vitro, with an IC50 of 27.6 µM.

7-51A is an effective inhibitor of the PB2 subunit of the influenza RNA-dependent RNA polymerase (RdRP), with a dissociation constant (K_D) of 1.64 nM as determined by isothermal titration calorimetry (ITC).

RdRP-IN-7, a RNA-dependent RNA polymerase (RdRp) inhibitor, demonstrates efficacy against SARS-CoV-2 infection with an inhibitory concentration (IC50) of 8.2 μM and (IC90) of 14.1 μM, alongside a cytotoxic concentration (CC90) of 79.1 μM, rendering it suitable for antiviral research [1].

EIDD-2749 (4'-FlU), a ribonucleoside analog, is an orally available RdRp inhibitor with spectroscopic antiviral activity that interrupts the replication of respiratory syncytial virus and SARS-CoV-2.EIDD-2749 attenuates lethal infections of pandemic human and highly pathogenic avian influenza viruses.

SHEN26 (ATY014) is a potent, orally active RdRp inhibitor with an IC50 of 1.36 μM for SARS-CoV-2. As a 5'-cyclohexanecarboxylate derivative of GS-441524, SHEN26 inhibits viral nucleic acid synthesis, achieving antiviral effects. SHEN26 can be used for COVID-19 research [1] [2].

MTI013 is a selective inhibitor of SARS-CoV-2 nsp14 Mtase (IC50: 2.98 µM) and an antiviral agent (IC50: 10.33 µM in HCoV-229E infected Huh7 cells). Additionally, MTI013 demonstrates synergistic antiviral effects when used in conjunction with the RdRp inhibitor SHEN26.

GSK5852 (GSK2485852) is an HCV NS5B RdRp polymerase inhibitor, inhibiting NS5B with an IC50 of 50 nM. It exhibits antiviral effects against the hepatitis C virus (HCV) with EC50 values of 3.0 nM for GT1a and 1.7 nM for GT1b.

Cis-Lomibuvir (cis-VX-222), a cis-isomer of Lomibuvir, is a selective non-nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase (RdRp), targeting thumb pocket 2 with a dissociation constant (Kd) of 17 nM. It exhibits an EC50 of 5.2 nM against the 1b Con1 HCV subgenomic replicon, demonstrating a preference for inhibiting elongative RNA synthesis over de novo-initiated RNA synthesis.